Zepzelca (Lurbinectedin) Patent Expiration, LOE Window & CMS Spending

Zepzelca (Lurbinectedin) by Jazz Pharmaceuticals: FDA Orange Book core substance LOE 2029-12-13, 0 AB generics, $19.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJazz Pharmaceuticals
FDA Application & PathwayN213702 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2029-12-13
Last Listed Patent or Exclusivity Date2029-12-13
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$19.9M
2024 Medicare Part D Spend$2.6M
2024 Medicaid Spend$17.3M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 18.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.